Guangdong Taienkang Pharmaceutical's subsidiary CKBA cream filed for clinical trials for children with vitiligo and was accepted.

Guangdong Taienkang Pharmaceutical (301263.SZ) announced that its controlling subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan"), has recently received an acceptance notification from the National Medical Products Administration, agreeing to accept Bochuangyuan's submission for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study application on the safety, tolerability, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrow-band ultraviolet B (NB-UVB) in children aged 2-12 years (including 2 years old) with non-segmental vitiligo.